Vistusertib: all 28 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
- Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsTerminatedNCT03366103Phase 1/2Results posted
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
- A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell MalignanciesTerminatedNCT03205046Phase 1/2Results posted
- AZD2014 In NF2 Patients With Progressive or Symptomatic MeningiomasCompletedNCT02831257Phase 2Results posted
- AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerCompletedNCT01597388Phase 1Results posted
- Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014CompletedNCT01026402Phase 1Results posted
- Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard ChemotherapyWithdrawnNCT03166904Phase 2
- Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard ChemotherapyWithdrawnNCT03166176Phase 2
- Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR AmplificationTerminatedNCT03106155Phase 2
- Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line ChemotherapyTerminatedNCT03082833Phase 2
- Vistusertib (AZD2014) For Recurrent Grade II-III MeningiomasStatus unknownNCT03071874Phase 2
- Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line TherapyTerminatedNCT03061708Phase 2
- AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
- Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)Active, not recruitingNCT02730923Phase 1/2
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma MultiformeCompletedNCT02619864Phase 1
- Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedNCT02599714Phase 1
- A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersStatus unknownNCT02583542Phase 1/2
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Japanese Phase I Study of AZD2014 in Advanced Solid MalignanciesCompletedNCT02398747Phase 1
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompletedNCT02216786Phase 2
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
- A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.CompletedNCT02193633Phase 1
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
- Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate CancerCompletedNCT02064608Phase 1
- A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal CancerTerminatedNCT01793636Phase 2